UK Charity Starts Early-Stage Clinical Studies Of Lilly's Cdc7 Inhibitor
Executive Summary
The drug development arm of the UK charity, Cancer Research UK, has started early clinical development of potentially a new type of anticancer, a Cdc7 inhibitor, discovered by Eli Lilly, in an effort that could boost traction in this new area of research.
You may also be interested in...
ProNAI Defects From Oligos to DDR As Sierra Oncology
Sierra Oncology president and CEO Dr Nick Glover tells Mike Ward how the company is rebranding itself from its former incarnation ProNAI Therapeutics, armed with two in-licensed assets focused of DNA damage repair (DDR) and $100m in the bank.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.